• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics establishes U.S. operations

May 26, 2016
CenterWatch Staff

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

“Our expansion into the U.S. in one of the world’s preeminent biotechnology hubs is an important step as we transition to a clinical-stage company with our first Bicycle Drug Conjugate program for oncology entering clinical testing next year,” said Kevin Lee, Ph.D., chief executive officer of Bicycle Therapeutics. “Ros brings proven experience in business development, finance, operations and commercial development.”

Deegan joined Bicycle Therapeutics from Trevena, where she most recently served on the senior leadership team as senior vice president, Business Development and Operations, and previously held the role of head of Finance and Operations. Prior to joining Trevena, Deegan was director of Business Development at GSK in the U.S. and, prior to that, she served as director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis.

“I am excited to join Bicycle, which has strong potential to create a new class of drugs with important advantages in delivering toxins to tumours, and broad applicability in a range of therapeutic areas,” said Deegan. “Bicyclic peptides hold the potential to deliver greater potency, specificity and penetration than current modalities, with more rapid clearance from the body. Our U.S. operations will play a central role for Bicycle as we advance our near-term oncology programs and enter collaborations across a range of diseases.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing